Industry > Industry monitor > Pharmaceuticals
23 April 2021
The Drug Controller General of India (DCGI) has granted Restricted Emergency Use Approval for Zydus Cadila’s Pegylated Interferon alpha-2b (PegIFN) or `Virafin’ for treating moderate Covid-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company stated in a release.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating Covid-19. The drug has also shown efficacy against other viral infections.
Zydus Cadila to sell its India focused animal health biz for Rs 2,921 cr to Multiples, RARE
By IANS |
Published on
Wed, May 12 2021 12:48 IST |
3 Views
Rupee. (File Photo: IANS). Image Source: IANS News
New Delhi, May 12 : Zydus Animal Health and Investments Limited (ZAHL) a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium.
Zydus AH is the animal health business of ZAHL focused on India and certain other countries. The consortium, including Canada Pension Plan Investment Board and RARE Enterprises has agreed to purchase the undertaking through an SPV controlled by them, in the name of Zenex Animal Health India Private Limited.
Zydus Cadila entity to sell its India focused Animal Health Business to Multiples Alternate Asset Management led consortium equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Zydus to sell animal healthcare business to Zenex for ₹2,921 crore
May 12, 2021
×
Inks agreement to sell businesses in India and some other countries by way of a slump sale
Cadila Healthcare Limited (Zydus Cadila) on Wednesday said its wholly-owned Zydus Animal Health and Investment Limited (ZAHL) has entered into a Business Transfer Agreement with Zenex Animal Health India Private Limited to sell itsanimal healthcare business.
Zydus will sell the Animal Healthcare Established Markets Undertaking - the animal healthcare business in India and certain other countries - by way of a slump sale- for an estimated consideration amount of ₹2,921 crore, subject to certain closing date adjustments in terms of the Definitive Agreements, the company said in a regulatory filing.